Novozymes (OTCMKTS: NVZMY) is one of 89 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Novozymes to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, earnings, dividends, profitability and valuation.
This is a breakdown of current ratings for Novozymes and its competitors, as reported by MarketBeat.
||Strong Buy Ratings
Novozymes currently has a consensus price target of $54.97, suggesting a potential upside of 9.79%. As a group, “Biological products, except diagnostic” companies have a potential upside of 36.60%. Given Novozymes’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Novozymes has less favorable growth aspects than its competitors.
Volatility & Risk
Novozymes has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Novozymes’ competitors have a beta of 1.59, indicating that their average share price is 59% more volatile than the S&P 500.
Insider and Institutional Ownership
0.2% of Novozymes shares are held by institutional investors. Comparatively, 48.0% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 16.6% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Novozymes pays an annual dividend of $0.49 per share and has a dividend yield of 1.0%. Novozymes pays out 30.8% of its earnings in the form of a dividend. As a group, “Biological products, except diagnostic” companies pay a dividend yield of 2.1% and pay out 35.7% of their earnings in the form of a dividend.
Valuation & Earnings
This table compares Novozymes and its competitors gross revenue, earnings per share (EPS) and valuation.
Novozymes has higher revenue and earnings than its competitors. Novozymes is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Novozymes and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Novozymes competitors beat Novozymes on 8 of the 15 factors compared.
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. It operates in three divisions: Household Care & Technical, Agriculture & Bioenergy, and Food & Beverages. The company offers enzymes for use in household care products, such as laundry detergents, hand and automatic dishwashing soaps, and professional cleaning products. It also provides enzymes for baking applications, including freshness, product appearance, dough improvement, etc.; and brewing applications comprising fermentation control, separation and filtration, etc., as well as for use in lactose-free dairy, trans fats removal, etc. in the food and beverages industry. In addition, the company offers enzymes and microorganisms for use in the production of cellulosic ethanol, starch-based ethanol, enzymatic biodiesel, and sugarcane ethanol in the bioenergy industry; and feed enzymes for use in animal feed, probiotics for animal health applications, microbials for aquaculture applications, and other enzymes and microorganisms for plant health and crop yield applications in the agriculture and feed industry. Further, it provides enzymes and microorganisms for use in textile processing, pulp and paper production, leather preparation, pharmaceuticals, and wastewater treatment solutions. The company has a strategic collaboration with Boehringer Ingelheim Animal Health for research and development, production, marketing, and sale of a portfolio of probiotic products. Novozymes A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Receive News & Ratings for Novozymes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes and related companies with MarketBeat.com's FREE daily email newsletter.